According to current state of knowledge, it is still not advised to prescribe GLP-1 agonists for individuals with a personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type-2 [24]. The gene discussed is GLP1R; the disease is medullary thyroid gland carcinoma.